Generated by Meeveem AI
"Developing novel treatments for infectious diseases and rare disorders since 1878"
Shionogi develops treatments for some of the world's most challenging infectious diseases and rare disorders. With research programmes spanning antimicrobial resistance, HIV, influenza and COVID-19, the company addresses critical unmet medical needs through science led drug discovery. Its portfolio includes novel antibiotics, antiviral medications and therapies for Fragile X syndrome. Founded in 1878 in Osaka, Japan, Shionogi operates globally with a focus on turning scientific excellence into patient outcomes. The company partners with government agencies, biotechnology firms and academic institutions to accelerate drug development and deliver meaningful solutions to communities facing urgent health threats.
4959
Team Members
1878
Founded
Pharma
Sector
Hybrid
Work Environment
A world where infectious diseases and rare disorders no longer limit human potential, where antimicrobial resistance is overcome, and where every patient has access to the treatments they need to live fully.
Shionogi exists to develop new treatments that improve patients' lives worldwide and supply the best possible medicines to aid the health and well-being of patients.